Dacetuzumab: Phase Ib data

Data from a dose-escalation Phase Ib trial in 36 patients with relapsed or refractory MM showed that 4-12 mg/kg dacetuzumab in combination with Revlimid lenalidomide and dexamethasone produced 2 comp...